Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Joong Bae Ahn1,800 enrolled

Overview

* Registry * Multicenter, prospective observational study * Observe adverse events and efficacy in recruited patients for 3 years under real world settings.

Study Type

OBSERVATIONAL

Enrollment

1,800

Conditions

Metastatic Colorectal Cancer

Interventions

FOLFIRI, target agentDRUG

* Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Bevacizumab * Irinotecan (Camtop Injection®, CJ HealthCare Corp.), Leucovorin, 5-Fluorouracil and Cetuximab

Eligibility

Sex: ALLMin age: 19 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Adult patients at least 19 years of age with metastatic colorectal cancer who are planned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen as first-line treatment 2. Patients who will receive irinotecan, a component of FOLFIRI regimen, using Camtop Injection® Exclusion Criteria: 1\) Patients with conditions in which any study drug is contraindicated per the respective approved label.

Locations (1)

Yonsei University Health System, Severance Hospital

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

percentage of use FOLFIRI regimen and target agents

Time frame: through study completion, 3 years

Central Contacts

Joong Bae Ahn

CONTACT

82-2-2228-8134

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.